Adult Ewing Sarcoma: Survival and Local Control Outcomes in 102 Patients with Localized Disease

Table 1

Patient characteristics and univariate analysis for overall  (OS) and event-free survival  (EFS)  (𝑛=102).

Variable	No. of patients  (%)	5-year OS (%)	𝑃	5-year EFS  (%)	𝑃
Sex
Male	69(68)	58	0.30	47	0.12
Female	33(32)	67		65
Age, years
Median	27.56
Range	18--60
18–25	46(45)	57	0.68	50	0.87
26–35	32(31)	63		53
36+	24(24)	64		56
Primary tumor site
Extremities	51(50)	60	0.90	52	0.95
Pelvis	17(17)	58		53
Axial	34(33)	63		53
Primary tumor site
Nonosseous	32(31)	60	0.65	52	0.72
Osseous	70(69)	60		52
Tumor size
<8 cm	38(58)	60	0.96	50	0.77
≥8 cm	27(42)	60		57
Treatment era
1977–1992	50(49)	49	0.01^∗	45	0.08
1993–2007	52(51)	73		60
LC modality
Surgery	43(42)	71	0.27	66	0.15
RT	25(25)	49		37
S + RT	34(33)	57		48
IE chemotherapy
No	37(42)	51	0.11	45	0.30
Yes	52(58)	66		56
Histopathologic response to chemotherapy
<95% necrosis	24(56)	49	0.04^∗	46	0.04^∗
≥95% necrosis	19(44)	83		77
Surgical margins
Clear	58(85)	69	0.008^∗	60	0.009^∗
Involved	10(15)	25		30
RT dose  (cGy) (definitive RT only)
<5600	19(83)	50	0.85	38	0.81
≥5600	4(17)	50		25

∗Statistically significant.